Advertisement
Review ArticleReview Article

Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair

Rina Aharoni, Ron Milo and Ruth Arnon
Francesca Levi-Schaffer, Associate Editor
Pharmacological Reviews November 2024, 76 (6) 1133-1158; DOI: https://doi.org/10.1124/pharmrev.124.000927
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Review ArticleReview Article

Glatiramer Acetate for the Treatment of Multiple Sclerosis

Rina Aharoni, Ron Milo and Ruth Arnon
Pharmacological Reviews November 1, 2024, 76 (6) 1133-1158; DOI: https://doi.org/10.1124/pharmrev.124.000927
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement